CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 876 enrolled
Drug / intervention
Cyclosporin A +6 moredrug
Likely dose
Antithymocyte globulin 7 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02487069
NCT02487069N/ACompleted
CompareCT.gov

Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy

Nanfang Hospital, Southern Medical University·interventional·Posted Jul 1, 2015·Updated Mar 5, 2020

In Brief

A clinical study evaluating HSCT from MSD, HSCT from MUD, and 5 other interventions for Acute Leukemia and 2 related conditions. Completed, enrolled 876 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the treatment of hematologic malignancy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
CountriesChina
CollaboratorsGuangdong Provincial People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou First People's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhujiang Hospital, Tongji Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Fujian Medical University Union Hospital, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 1, 2015
Enrollment StartJun 1, 2015
Primary CompletionJan 31, 2020
Study CompletionFeb 29, 2020
TodayJul 1, 2026
Enrollment to primary: 4.7 yearsPosted 11 years ago

Interventions

HSCT from MSDprocedure

HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.

HSCT from MUDprocedure

HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.

HSCT from HRDprocedure

HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.

Cyclosporin Adrug

CsA is used in all the patients for GVHD prophylaxis.

Methotrexatedrug

MTX is used in all the patients for GVHD prophylaxis.

Antithymocyte globulindrug

ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.

Mycophenolate mofetildrug

MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.